Company intelligence / Profile preview

Viventia

Winnipeg, Manitoba, Canada

Ownership: Private
Development stage: Other

Overview

Viventia's lead program, vicinium, advanced to Phase 3 for non-muscle invasive bladder cancer with promising preliminary efficacy. Proxinium, targeting head and neck cancers, entered Phase 2 and received orphan drug and Fast Track designations in the US and EU. The company had a broader preclinical pipeline including multiple targeted protein therapeutics using antibody fragment-fusion toxin constructs.[6]

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibodyProtein
Industry: Biotech

Beyond the preview

Go deeper on Viventia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viventia.

Explore the full profile